الفهرس | Only 14 pages are availabe for public view |
Abstract The aim of the present study is to evaluate changes in intraocular pressure following intravitreal injections of different doses of bevacizumab. This is a prospective, randomized, comparative clinical study that was conducted on 60 eyes of 60 patients. Patients who were scheduled for intravitreal injection of bevacizumab due to diabetic macular edema (DME), cystoid macular edema (CME), choroidal neovascular membrane (CNVM), branch and central retinal vein occlusion (BRVO and CRVO) and proliferative diabetic retinopathy (PDR). They were randomly divided into 2 groups. group A: 30 eyes were scheduled for intravitreal injection of bevacizumab 0.1 ml (2.5 mg). The mean age was (59.80 ± 7.27 years). group B: 30 eyes were scheduled for intravitreal bevacizumab 0.05 ml (1.25 mg). The mean age was (59.83 ± 6.29 years). IOP was measured using goldmann applanation tonometer before the injection, IOP was measured before and after bevacizumab injection at 15 minutes, 30 minutes, 24 hours and 7 days after injection |